Skip to main content

Table 2 Cox multivariate analysis of recurrence/mortality in patients without adjuvant therapy

From: Differences in clinical importance of Bcl-2 in breast cancer according to hormone receptors status or adjuvant endocrine therapy

 

Total

ER+ and/or PR+

ER- and PR-

ER-/PR-/HER2-

HR (95% CI)

P-value

HR (95% CI)

P-value

HR (95% CI)

P-value

HR (95% CI)

P-value

Recurrence

PostM vs. PreM

0.893 (0.598-1.329)

0.5774

1.167 (0.721-1.887)

0.5268

0.813 (0.419-1.548)

0.5300

0.866 (0.378-1.921)

0.7248

T (>2cm vs. ≤2cm)

0.887 (0.601-1.315)

0.5488

0.895 (0.548-1.460)

0.6573

0.900 (0.469-1.796)

0.7572

0.823 (0.388-1.823)

0.6212

LN (+ vs. -)

2.933 (1.978-4.323)

<0.0001*

2.451 (1.488-4.018)

0.0005*

3.879 (1.973-7.414)

0.0002*

3.522 (1.484-7.793)

0.0056*

Grade (II+III vs. I)

2.121 (1.294-3.649)

0.0024*

2.182 (1.274-3.921)

0.0039*

2.056 (0.600-12.900)

0.2844

1.947 (0.560-12.290)

0.3309

ER (+ vs. -)

0.723 (0.444-1.193)

0.2026

      

PR (+ vs. -)

0.588 (0.370-0.931)

0.0235*

      

HER2 (+ vs. -)

1.313 (0.720-2.282)

0.3617

0.947 (0.227-2.660)

0.9276

1.563 (0.754-3.138)

0.2237

  

Bcl-2 (+ vs. -)

2.544 (1.512-4.351)

0.0004*

1.568 (0.759-3.802)

0.2398

3.369 (1.681-6.755)

0.0007*

3.321 (1.556-7.231)

0.0021*

Mortality

PostM vs. PreM

0.914 (0.592-1.407)

0.6829

1.252 (0.721-2.174)

0.4219

0.807 (0.418-1.529)

0.5137

0.877 (0.385-1.928)

0.7455

T (>2cm vs. ≤2cm)

1.008 (0.657-1.563)

0.9705

1.098 (0.628-1.933)

0.7436

0.917 (0.470-1.872)

0.8058

0.862 (0.399-1.965)

0.7139

LN (+ vs. -)

3.186 (2.082-4.853

<0.0001*

2.701 (1.532-4.769)

0.0007*

3.749 (1.907-7.178)

0.0002*

3.425 (1.444-7.576)

0.0065*

Grade (II+III vs. I)

2.431 (1.364-4.672)

0.0020*

2.577 (1.358-5.316)

0.0031*

1.871 (0.547-11.728)

0.3575

1.795 (0.519-11.302)

0.3963

ER (+ vs. -)

0.602 (0.354-1.032)

0.0646

      

PR (+ vs. -)

0.534 (0.316-0.894)

0.0169*

      

HER2 (+ vs. -)

1.406 (0.762-2.485)

0.2667

1.237 (0.293-3.557)

0.7363

1.653 (0.795-3.337)

0.1742

  

Bcl-2 (+ vs. -)

2.399 (1.385-4.205)

0.0017*

1.222 (0.578-3.004)

0.6210

3.143 (1.559-6.306)

0.0016*

3.081 (1.432-6.719)

0.0043*

  1. Factors considered other than Bcl-2 is menopausal status, tumor size, nodal status, grade, ER, PR and HER2 status
  2. ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, HR hazard ratio, PostM and PreM postmenopause and premenopause at the time of diagnosis, T tumor size, LN lymph node, + positive; − negative
  3. *Significant, P < 0.05.